טריטייס  קומפ 2.5 מג  12.5 מג ישראל - עברית - Ministry of Health

טריטייס קומפ 2.5 מג 12.5 מג

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

טריטייס קומפ 5 מג  25 מג ישראל - עברית - Ministry of Health

טריטייס קומפ 5 מג 25 מג

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

קו-דיובאן 8012.5 מג טבליות מצופות ישראל - עברית - Ministry of Health

קו-דיובאן 8012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

קו-דיובאן 16012.5 מג טבליות מצופות ישראל - עברית - Ministry of Health

קו-דיובאן 16012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

קו-דיובאן 16025 מג טבליות מצופות ישראל - עברית - Ministry of Health

קו-דיובאן 16025 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

אוויסטה ישראל - עברית - Ministry of Health

אוויסטה

eli lilly israel ltd, israel - raloxifene hydrochloride - טבליות מצופות פילם - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - evista is indicated for the treatment of osteoporosis in post menopausal women. evista is indicated for the prevention of osteoporosis in post menopausal women . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

ראלוקסיפן טבע ישראל - עברית - Ministry of Health

ראלוקסיפן טבע

teva israel ltd - raloxifene hydrochloride - טבליה - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .

ראלוקסיפן טבע ישראל - עברית - Ministry of Health

ראלוקסיפן טבע

teva israel ltd - raloxifene hydrochloride - טבליה - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .

ספזמקס 15 ישראל - עברית - Ministry of Health

ספזמקס 15

tec-o-pharm-libra ltd - trospium chloride - טבליות מצופות פילם - trospium chloride 15 mg - trospium - trospium - for the treatment of vegetative bladder dysfunction, urge and reflex incontinence.

זיבוקסיד 600 מג ישראל - עברית - Ministry of Health

זיבוקסיד 600 מג

pfizer pfe pharmaceuticals israel ltd - linezolid - טבליה - linezolid 600 mg - linezolid - linezolid - therapy is indicated only when an organism resistant to all other antibiotics is suspected. zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (mdrsp). 2) skin and soft tissue infections including diabetic foot infections. 3) enterococcal infections. combination therapy may be indicated if a concomitant gram negative pathogen is documented or suspected.